FunPep Company Limited (4881.T)
JPY 131.0
(0.77%)
JPY 131.0
(0.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -952 Million JPY | 17.71% |
| 2022 | -1.15 Billion JPY | -55.05% |
| 2021 | -745.04 Million JPY | -32.21% |
| 2020 | -563.51 Million JPY | -99.09% |
| 2019 | -283.93 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -183.52 Million JPY | 8.33% |
| 2024 Q2 | -201.43 Million JPY | -17.11% |
| 2023 Q2 | -243.83 Million JPY | 35.62% |
| 2023 Q4 | -188.16 Million JPY | -2.62% |
| 2023 Q1 | -378.75 Million JPY | -9.45% |
| 2023 FY | - JPY | 17.71% |
| 2023 Q3 | -183.35 Million JPY | 24.8% |
| 2022 Q3 | -295.39 Million JPY | 0.0% |
| 2022 FY | - JPY | -55.05% |
| 2022 Q4 | -346.03 Million JPY | -17.14% |
| 2021 FY | - JPY | -32.21% |
| 2020 FY | - JPY | -99.09% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 199.363% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -95.029% |
| GNI Group Ltd. | 14.48 Billion JPY | 106.571% |
| Linical Co., Ltd. | 1.24 Billion JPY | 176.329% |
| Trans Genic Inc. | 240.95 Million JPY | 495.099% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 29.786% |
| Soiken Holdings Inc. | -583.2 Million JPY | -63.236% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -57.853% |
| AnGes, Inc. | -8.86 Billion JPY | 89.255% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 25.943% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 87.133% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 843.129% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -10.313% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 12.803% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1874.431% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -22.745% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -751.513% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 21.435% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 31.056% |
| PeptiDream Inc. | 7.37 Billion JPY | 112.907% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 50.666% |
| Ribomic Inc. | -1.01 Billion JPY | 5.978% |
| SanBio Company Limited | -4.52 Billion JPY | 78.961% |
| Healios K.K. | -3 Billion JPY | 68.341% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 18.338% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 31.662% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 32.097% |
| StemRIM | -2.03 Billion JPY | 53.15% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 172.87% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -7.115% |
| Stella Pharma Corporation | -723.85 Million JPY | -31.518% |
| TMS Co., Ltd. | -937 Million JPY | -1.601% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -22.777% |
| Cuorips Inc. | -518 Million JPY | -83.784% |
| K Pharma,Inc. | 366.05 Million JPY | 360.068% |
| Takara Bio Inc. | 8.02 Billion JPY | 111.864% |
| ReproCELL Incorporated | 8.24 Million JPY | 11646.392% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1182.581% |
| StemCell Institute Inc. | 534.35 Million JPY | 278.159% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 488.867% |
| CellSeed Inc. | -836.51 Million JPY | -13.805% |